Ruben Varela-Calvino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4779066/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CTLs are targeted to kill \hat{I}^2 cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. Journal of Clinical Investigation, 2008, 118, 3390-402.	8.2	315
2	Protein architecture of avian reovirus S1133 and identification of the cell attachment protein. Journal of Virology, 1997, 71, 59-64.	3.4	96
3	Cellular Immune Activation in Gulf War Veterans. Journal of Clinical Immunology, 2004, 24, 66-73.	3.8	58
4	Intracellular posttranslational modifications of S1133 avian reovirus proteins. Journal of Virology, 1996, 70, 2974-2981.	3.4	48
5	Endogenous Enzymatic Activities of the Avian Reovirus S1133: Identification of the Viral Capping Enzyme. Virology, 1995, 206, 1017-1026.	2.4	40
6	Characterization of the T-Cell Response to Coxsackievirus B4: Evidence That Effector Memory Cells Predominate in Patients With Type 1 Diabetes. Diabetes, 2002, 51, 1745-1753.	0.6	37
7	Enteroviruses and type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2003, 19, 431-441.	4.0	34
8	Identification of a Naturally Processed Cytotoxic CD8 T-Cell Epitope of Coxsackievirus B4, Presented by HLA-A2.1 and Located in the PEVKEK Region of the P2C Nonstructural Protein. Journal of Virology, 2004, 78, 13399-13408.	3.4	31
9	T-Cell Reactivity to the P2C Nonstructural Protein of a Diabetogenic Strain of Coxsackievirus B4. Virology, 2000, 274, 56-64.	2.4	27
10	Oral hygiene might prevent cancer. Heliyon, 2018, 4, e00879.	3.2	23
11	Role of the capsid protein VP4 in the plasma-dependent enhancement of the Coxsackievirus B4E2-infection of human peripheral blood cells. Virus Research, 2007, 125, 183-190.	2.2	20
12	Autoantibodies to glial fibrillary acid protein and S100β in diabetic patients. Diabetic Medicine, 2010, 27, 246-248.	2.3	19
13	CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0131992.	2.5	19
14	A chitosan-based nanosystem as pneumococcal vaccine delivery platform. Drug Delivery and Translational Research, 2021, 11, 581-597.	5.8	19
15	T Cell Activation by Coxsackievirus B4 Antigens in Type 1 Diabetes Mellitus: Evidence for Selective TCR Vβ Usage Without Superantigenic Activity. Journal of Immunology, 2001, 167, 3513-3520.	0.8	17
16	Human peripheral blood mononuclear cell in vitro system to test the efficacy of food bioactive compounds: Effects of polyunsaturated fatty acids and their relation with BMI. Molecular Nutrition and Food Research, 2017, 61, 1600353.	3.3	17
17	HLA Class II molecules on haplotypes associated with type 1 diabetes exhibit similar patterns of binding affinities for coxsackievirus P2C peptides. Immunology, 2005, 116, 337-346.	4.4	15
18	Anti-CD26 autoantibodies are involved in rheumatoid arthritis and show potential clinical interest. Clinical Biochemistry, 2017, 50, 903-910.	1.9	13

RUBEN VARELA-CALVINO

#	Article	IF	CITATIONS
19	Apportioning Blame: Autoreactive CD4+ and CD8+ T Cells in Type 1 Diabetes. Archivum Immunologiae Et Therapiae Experimentalis, 2017, 65, 275-284.	2.3	12
20	Design of polymeric nanocapsules to improve their lympho-targeting capacity. Nanomedicine, 2019, 14, 3013-3033.	3.3	12
21	CD26-Related Serum Biomarkers: sCD26 Protein, DPP4 Activity, and Anti-CD26 Isotype Levels in a Colorectal Cancer-Screening Context. Disease Markers, 2020, 2020, 1-10.	1.3	12
22	Galectin-1 synthesis in type 1 diabetes by different immune cell types: Reduced synthesis by monocytes and Th1 cells. Cellular Immunology, 2011, 271, 319-328.	3.0	10
23	Characterization of the autoimmune response against the nerve tissue S100β in patients with type 1 diabetes. Clinical and Experimental Immunology, 2015, 180, 207-217.	2.6	10
24	The mechanism of sitagliptin inhibition of colorectal cancer cell lines' metastatic functionalities. IUBMB Life, 2021, 73, 761-773.	3.4	8
25	Naturally presented HLA class l–restricted epitopes from the neurotrophic factor S100â€Î² are targets of the autoimmune response in type 1 diabetes. FASEB Journal, 2019, 33, 6390-6401.	0.5	6
26	3Â Hydroxysteroid Dehydrogenase Autoantibodies in Patients with Idiopathic Premature Ovarian Failure Target N- and C-Terminal Epitopes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5892-5897.	3.6	6
27	Functional assessment of the <i><scp>BMPR</scp>2</i> gene in lymphoblastoid cell lines from Graves' disease patients. Journal of Cellular and Molecular Medicine, 2018, 22, 1538-1547.	3.6	4
28	Serum dipeptidyl peptidase IV activity and sCD26 concentration in patients with choroidal nevus or uveal melanoma. Clinica Chimica Acta, 2015, 448, 193-194.	1.1	3
29	IC-Tagging methodology applied to the expression of viral glycoproteins and the difficult-to-express membrane-bound IGRP autoantigen. Scientific Reports, 2018, 8, 16286.	3.3	3
30	Distinctive CD26 Expression on CD4 T-Cell Subsets. Biomolecules, 2021, 11, 1446.	4.0	3
31	Study of Plasma Anti-CD26 Autoantibody Levels in a Cohort of Treatment-NaÃ⁻ve Early Arthritis Patients. Archivum Immunologiae Et Therapiae Experimentalis, 2022, 70, 12.	2.3	2
32	Tissue-polypeptide-specific antigen levels in diabetic patients with normal and pathological biochemical profiles. Clinical Biochemistry, 2007, 40, 278-281.	1.9	1
33	CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. Journal of Clinical Investigation, 2009, 119, 2843-2843.	8.2	1
34	Stem and immune cells in colorectal primary tumour: Number and function of subsets may diagnose metastasis. World Journal of Immunology, 2015, 5, 68.	0.5	1
35	Immunology and Immunotherapy of Colorectal Cancer. , 2020, , 261-289.		1

Bioinspired pollen microcapsules to overcome mucosal barriers. , 2021, , .

0

#	Article	IF	CITATIONS
37	Analysis ofBMPR2gene expression in B-lymphocytes of pulmonary arterial hypertension patients. , 2016, , .		0

Immunology and immunotherapy in CRC. , 2022, , 435-453.